RBC raises target for Gilead Sciences stock to USD 126.00

Published on 10/09/2026 at 16:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue hit USD 7.80 billion versus USD 7.40 billion consensus. Gilead Sciences stock costs EUR 133.75 after EUR 131.21 on October 9, 2026.

Key points in brief

RBC raised its Gilead Sciences price target from USD 123.00 to USD 126.00 on October 8, 2026, while keeping a Sector Perform rating.
Second-quarter 2026 revenue reached USD 7.80 billion against USD 7.40 billion consensus, according to MarketBeat.
Gilead Sciences stock was trading at EUR 133.75 at Lang & Schwarz on October 9, 2026, plus 1.94 percent versus the prior close.
The company lifted full-year 2026 HIV growth guidance to 9.00-10.00 percent from 8.00 percent after second-quarter HIV sales of USD 5.70 billion.

Schwarzweiß-Reportage: Gilead Sciences Forscherin am Mikroskop im Biopharma-Labor — Gilead Sciences ISIN US3755581036 Schwarzweiß-Reportage Forscherin untersucht Zellkulturen am Mikroskop im Labor, Illustration mit AI erstellt.

Gilead Sciences (ISIN US3755581036) was trading at EUR 133.75 at Lang & Schwarz on October 9, 2026 at 4:16 p.m. CEST, plus 1.94 percent versus EUR 131.21. As The Globe and Mail reported on October 8, 2026, RBC Capital Markets raised its price target from USD 123.00 to USD 126.00 and maintained a Sector Perform rating.

What changed in the target?

The RBC move followed a stronger operating picture in the second quarter, but its USD 126.00 target remains a separate US-dollar benchmark from the euro quote. The NASDAQ-listed biopharmaceutical company has a market capitalization of USD 185.6 billion as of October 9, 2026, with a 52-week range of USD 114.02 to USD 157.29.

Truist had already raised its target from USD 150.00 to USD 158.00 on October 7, 2026, while maintaining a Buy rating, according to MarketBeat. The split between RBC's Sector Perform view and Truist's Buy rating puts the current valuation in the center of the debate.

What does HIV growth mean for revenue?

Gilead reported second-quarter 2026 revenue of USD 7.80 billion against USD 7.40 billion consensus, while the quarter's diluted loss per share was USD 6.75 versus a USD 7.25 consensus loss, MarketBeat reported. The result combines revenue growth with acquisition-related costs that weighed heavily on reported earnings.

In its second-quarter earnings call dated August 4, 2026, Gilead said HIV sales rose 12.00 percent year over year to USD 5.70 billion and lifted full-year 2026 HIV growth guidance to 9.00-10.00 percent from 8.00 percent, according to Yahoo Finance. That guidance gives the business a quantified growth driver beyond the analyst target changes.

Three milestones shape the setup

On August 3, 2026, Gilead reported second-quarter revenue of USD 7.80 billion and a diluted loss per share of USD 6.75, according to MarketBeat. On August 4, 2026, management disclosed the 12.00 percent HIV sales increase and the higher 9.00-10.00 percent growth outlook, according to Yahoo Finance. On October 8, 2026, RBC lifted its target to USD 126.00 from USD 123.00, according to The Globe and Mail.

Which dates come next?

Investing.com lists October 21, 2026 as the next earnings date. The earnings-call transcript also points to February 2, 2027 for a regulatory decision on once-weekly oral lenacapavir for HIV prevention, according to Yahoo Finance.

Gilead stock holds a quantified range

At EUR 133.75, Gilead Sciences stock was trading in the October 9, 2026 session at Lang & Schwarz, up 1.94 percent from the EUR 131.21 prior close. The next market read will combine the October 21, 2026 earnings date with the gap between reported revenue growth and the cost burden from recent acquisitions.

The further course of trading is shown by the continuously updated real-time quote of Gilead Sciences stock.